Daewoong’s Ursa mired in efficacy dispute

Published: 2013-09-10 07:00:00

Updated: 2013-09-10 07:00:00

Daewoong Pharmaceutical, one of the country's biggest drug makers, has built its reputation on its immensely popular liver medicine, Ursa (ursodeoxycholic acid; UDCA), but its efficacy is mired in controversy due to a report by a local media.

Last Friday, the media argued that Ursa is almost s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK